Is Hologic Stock Underperforming the S&P 500?

Core Viewpoint - Hologic, Inc. is focused on women's health and has shown resilience in its financial performance despite recent stock declines, with strategic acquisitions aimed at growth in the oncology market [1][2][7]. Financial Performance - Hologic's revenue for the third quarter of fiscal 2025 was $1.02 billion, a 1.2% year-over-year increase, surpassing Wall Street's expectation of $1.01 billion [6]. - The company's adjusted EPS was $1.08, which is 1.9% higher than the previous year and exceeded the expected $1.05 [6]. - The non-GAAP net margin decreased by 100 basis points year-over-year to 23.8% [6]. Stock Performance - Hologic's stock reached a 52-week low of $51.90 in May 2025 but has since increased by 27.8% from that low [3]. - Over the past 52 weeks, Hologic's shares have declined by 19.5%, and they are down 8% year-to-date, while the S&P 500 index has gained 16.6% and 13.3% over the same periods, respectively [4]. - Following the third-quarter earnings report, the stock initially dropped by 1.6% but rebounded with a 2.8% increase the following day [5]. Strategic Acquisitions - Hologic is pursuing growth through strategic acquisitions, including the 2021 acquisition of Biotheranostics, which expanded its presence in the oncology market [7]. - The recent acquisition of Gynesonics is expected to further strengthen Hologic's market position [7].